TL;DR: This blog dispels common misconceptions about thyroid radiofrequency ablation (RFA) and clarifies its role as a safe, effective, and evidence-based alternative to surgery for benign thyroid nodules. Drawing on recent clinical data and consensus guidance, it separates persistent myths from current medical reality.
- Thyroid RFA is well established, with multiple studies showing 50–80% nodule volume reduction within 6–12 months while preserving thyroid function.
- RFA is not limited to small nodules and can be effective for larger and autonomously functioning nodules, sometimes with more than one treatment session.
- Clinical outcomes are comparable to surgery for benign nodules, with faster recovery and a significantly lower risk of permanent hypothyroidism.
- Insurance coverage has expanded, supported by the introduction of CPT Category I codes for percutaneous thyroid RFA in the U.S.
- The procedure has a strong safety profile, with low complication rates and fewer serious risks than surgical thyroidectomy.
Thyroid radiofrequency ablation (RFA) is emerging as a minimally invasive treatment for benign thyroid nodules. Though this treatment modality is in use worldwide, various myths about the use of RFA for thyroid still persist among clinicians. This misinformation may stand in the way of providing patients with a safe, outpatient treatment option.
In this blog, we’ll debunk five common myths about RFA for thyroid nodules with evidence. Continue reading to learn the truth behind RFA thyroid treatments so you can confidently offer patients a proven, in-office alternative to open surgery.
Myth: Thyroid Radiofrequency Ablation Is Experimental or Unproven
Thyroid RFA is a well-established treatment with extensive clinical validation. Multiple studies published within the last five years demonstrate consistent 50 to 80% thyroid nodule volume reduction within 6 to 12 months. The same studies demonstrate symptom and cosmetic improvement and preservation of thyroid function.
As a result, thyroid RFA is included in several international consensus statements and clinical recommendations for benign nodules.
Myth: RFA for Thyroid Nodules Is Only Appropriate for Small Nodules
RFA for thyroid nodules is appropriate for a wide range of benign nodules (and, increasingly, even malignant nodules), including large and autonomously functioning nodules. Larger nodules may require more than one session, but outcomes remain favorable.
Myth: Surgery Is More Effective Than RFA Thyroid Treatment
For benign nodules, outcomes with RFA for thyroid nodules are comparable to surgery in terms of symptom relief and nodule reduction. Unlike surgery, thyroid RFA preserves normal thyroid tissue and significantly reduces the risk of permanent hypothyroidism. Most patients resume normal activities within 48 hours after treatment, if not sooner.
Myth: Thyroid RFA Is Not Covered by Insurance
Insurance coverage for thyroid radiofrequency ablation has expanded significantly. In the United States. CPT Category I codes are now available for percutaneous thyroid RFA, reflecting its acceptance as a standard-of-care treatment.
Myth: The RFA Thyroid Procedure Is Risky
The RFA procedure for the thyroid has a strong safety profile when performed by trained clinicians using ultrasound guidance and established techniques. Reported complication rates are low, with most adverse events being mild and transient. Serious complications are rare and occur less frequently than with surgical thyroidectomy.
Learn More About Thyroid Radiofrequency Ablation
For clinicians, RFA thyroid treatment offers a minimally invasive, in-office alternative to surgery that appeals to patients. To learn more about thyroid RFA and how to offer your patients a minimally invasive, in-office procedure, visit STARmed America’s Thyroid RFA resource center.
